Magvit, 50 mg+5 mg capsules 50 pcs

Magnesium is predominantly an intracellular cation. It reduces neuronal excitability and neuromuscular transmission of excitation, takes part in many enzymatic processes.

Magnesium is an essential element of organs and tissues: in the bone tissue is half of the total amount of magnesium in the human body.

The clinical aspects:

Serum magnesium levels:

• between 12 and 17 mg/L (1 – 1.4 mEq/L or 0.5 – 0.7 mmol/L): indicate moderate magnesium deficiency

• below 12 mg/L (1 mEq/L or 0.5 mmol/L): indicate severe magnesium deficiency.

Deficiency can be:

• primary, due to a congenital abnormality of magnesium metabolism,

• secondary, due to: inadequate intake (severe malnutrition, alcoholism, total parenteral nutrition); gastrointestinal absorption disorders (chronic diarrhea, gastrointestinal fistula, hypoparathyroidism); excessive renal losses (tubular disease, significant polyuria, diuretic abuse, chronic pyelonephritis, primary hyperaldosteronism, cisplatin treatment).

Pyridoxine (vitamin B6) is involved in many metabolic processes, in the regulation of metabolism of the nervous system. Vitamin B6 in Magvit improves the absorption of magnesium from the gastrointestinal tract and its penetration into cells.

The use of the combined product containing magnesium citrate and vitamin B6 is justified by the following data:

• vit. B6 and magnesium complement each other’s pharmacological actions;

• Vit. B6 increases magnesium concentrations in the plasma and red blood cells and decreases the amount of magnesium in the body. B6 improves the absorption of magnesium from the gastrointestinal tract and its penetration into cells;

• Magnesium increases the conversion of pyridoxine to its active metabolite, pyridoxal-5-phosphate, in the liver;

• Vit. B6 helps increase intracellular magnesium.

The water-soluble organic magnesium salt (magnesium citrate) in the product is well absorbed, and pyridoxine further increases magnesium absorption and entry into the cells.

Pharmacokinetics

Intake and distribution

About 50% of magnesium is absorbed from the gastrointestinal tract after ingestion. In the body, magnesium is distributed mainly in the intracellular space (about 99%), of which about 2/3 is distributed in bone tissue and a third is in smooth and transverse striated muscle tissue.

Pyridoxine is absorbed in the small intestine, is transported with the bloodstream to tissues and, penetrating into cells, is phosphorylated with ATP and pyridoxal kinases.

The primary route of magnesium excretion is through the urinary system. The renal tubules reabsorb 70% of the magnesium present in the plasma, 95-97% of which is then reabsorbed in the renal tubules. Magnesium present in the urine is, on average, one third of the ingested magnesium.

The main product of pyridoxine catabolism is 4-pyridoxylic acid, which is excreted in the urine.

Indications

The drug “Magvit” contains magnesium, a deficiency of which in the body may be indicated by the following symptoms:

• nervousness, irritability, mild anxiety, transient fatigue, minor sleep disturbances,

• manifestation of anxiety in the form of gastrointestinal cramps, rapid heartbeat (if the heart is healthy),

• muscular cramps, tingling sensation.

Prescribing magnesium may help relieve these symptoms.

If there is no improvement after one month of treatment, it is not appropriate to continue with Magvit monotherapy.

Composition

Pyridoxine hydrochloride – 5 mg, magnesium in the form of magnesium citrate – 50 mg.

Interaction

When concomitant use of Magvit and drugs containing phosphates and calcium salts, absorption of magnesium from the gastrointestinal tract may be significantly reduced.

The drug reduces the absorption of iron, absorption of tetracycline.

If used together, magnesium weakens the effect of oral thrombolytics.

Pyridoxine increases the effect of diuretics; it significantly reduces the antiparkinsonian effect of levodopa; it combines well with cardiac glycosides (increases the synthesis of contractile proteins in the myocardium), with glutamic acid and asparticam (increases resistance to hypoxia).

Directions for use

In the complex treatment of magnesium deficiency in the body, according to the instructions for use, Magvit is administered orally to adults and children over 6 years, 1-2 capsules 2-3 times a day with meals.

The treatment should be discontinued after normalization of the magnesium concentration in the blood.

Special Instructions

In concomitant calcium deficiency, magnesium deficiency in the body should be corrected before starting calcium preparations.

In severe magnesium deficiency and absorption disorders, treatment should be initiated intravenously.

If tetracycline and Magvit are used together, a 3-hour interval between doses of these drugs should be observed.

In frequent use of laxatives, ethanol, high mental and physical exertion increases the need for magnesium and increases the risk of magnesium deficiency in the body.

Because of the presence of lactose in the capsules, the drug is contraindicated for patients with congenital galactose intolerance, Lap lactase deficiency, and galactose-glucose malabsorption.

The dyes included in the capsule shell may cause allergic reactions.

This dosage form is not prescribed for children under 6 years of age.

In moderate renal insufficiency, caution should be exercised to prevent the risk associated with hypermagnesemia.

Long-term use (several months or years) of vitamin B6 (>200 mg/day) causes sensory neuropathies, which are usually reversible after discontinuation of therapy.

“Magvit” in pregnancy can be used only with indications and under medical supervision.

Contraindications

Contraindication to the use of Magvit according to the instructions is hypersensitivity to its components, as well as marked renal failure (CK less than 30 ml/min), hypermagnesemia, children under 6 years of age.

With caution: in moderate renal function insufficiency, because there is a risk of hypermagnesemia.

Overdose

In normal renal function, ingestion of magnesium does not cause toxic reactions. Magnesium poisoning may develop in renal failure. Toxic effects mainly depend on the content of magnesium in the blood.

Symptoms: drop in BP, nausea, vomiting, central nervous system depression, loss of reflexes, respiratory depression, coma, cardiac arrest and respiratory paralysis, ECG abnormalities, anuria.

Treatment: rehydration, forced diuresis.

In case of renal failure, hemodialysis or peritoneal dialysis is necessary.

Pregnancy use

During pregnancy, “Magvit” may be used only with indications and under medical supervision.

The drug is not recommended to use during breast-feeding. Magnesium is excreted with the breast milk.